Pharmaceutical major Lupin said that it has launched the generic equivalent of Eli Lilly’s Cialis erectile dysfunction tablets.
Lupin had received the approval from the United States Food and Drug Administration to sell the tablets along with its rivals Zydus Cadila, Unichem Laboratories and Alembic Pharmaceuticals on March 27.
Tadalafil tablets are used to treat erectile dysfunction, benign prostatic hyperplasia and pulmonary arterial hypertension.
The drug, which competes with Viagra and others, will be sold in the doses of 2.5 mg, 5 mg, 10 mg and 20 mg.
As of December 2018, the tablet had an annual sales of $1780 million in the US market.
Lupin is one of the world’s biggest makers of generic drugs, and sells both branded and generic formulations, biotechnology products and pharmaceutical ingredients globally.
It is the world’s biggest manufacturer of anti-TB medicines and focuses on cardiovascular, diabetology, asthma, paediatric, CNS, GI, anti-infective and NSAID segments of the pharma market.